stoxline Quote Chart Rank Option Currency Glossary
  
Ocular Therapeutix, Inc. (OCUL)
11.33  -0.05 (-0.44%)    07-18 16:00
Open: 11.56
High: 11.56
Volume: 2,100,126
  
Pre. Close: 11.38
Low: 11.23
Market Cap: 1,805(M)
Technical analysis
2025-07-18 4:43:27 PM
Short term     
Mid term     
Targets 6-month :  13.5 1-year :  15.77
Resists First :  11.56 Second :  13.5
Pivot price 10.35
Supports First :  9.37 Second :  8.02
MAs MA(5) :  11.26 MA(20) :  9.98
MA(100) :  8.08 MA(250) :  8.55
MACD MACD :  0.7 Signal :  0.6
%K %D K(14,3) :  92.2 D(3) :  91.9
RSI RSI(14): 75.2
52-week High :  11.77 Low :  5.78
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OCUL ] has closed below upper band by 22.2%. Bollinger Bands are 74.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.57 - 11.63 11.63 - 11.69
Low: 11.09 - 11.16 11.16 - 11.21
Close: 11.22 - 11.33 11.33 - 11.43
Company Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Headline News

Wed, 09 Jul 2025
Ocular Therapeutix(OCUL) Soars 8.47% on Pipeline Progress - AInvest

Mon, 07 Jul 2025
Institutional investors control 65% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 3.7% - simplywall.st

Thu, 26 Jun 2025
Ocular Therapeutix Launches New Corporate Branding to Enhance Retina-Focused Mission - Nasdaq

Thu, 26 Jun 2025
Ocular Therapeutix Pivots to $14B Retina Market with Revolutionary AMD Treatment Platform - Stock Titan

Thu, 26 Jun 2025
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - GlobeNewswire

Wed, 25 Jun 2025
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 159 (M)
Shares Float 122 (M)
Held by Insiders 3.8 (%)
Held by Institutions 87 (%)
Shares Short 14,420 (K)
Shares Short P.Month 13,830 (K)
Stock Financials
EPS -1.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.66
Profit Margin 0 %
Operating Margin -597.5 %
Return on Assets (ttm) -27.3 %
Return on Equity (ttm) -57.2 %
Qtrly Rev. Growth -27.7 %
Gross Profit (p.s.) -0.61
Sales Per Share 0.37
EBITDA (p.s.) -1.27
Qtrly Earnings Growth 0 %
Operating Cash Flow -145 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -10.21
PEG Ratio 0
Price to Book value 6.78
Price to Sales 30.25
Price to Cash Flow -12.41
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android